Special permission could be granted to Japan for use of the corona cocktail next week, according to a report published on the website of the country’s public broadcaster, NHK.
The cocktail developed by U.S.-based Regeneron Pharmaceuticals was used on Donald Trump last year when the former president contracted COVID-19, better known as the plague of modern times.
What’s the recipe for this fabulous cocktail? It contains only two antibodies: casirivimab and imdevimab. It reportedly reduces hospitalization and death by 70 percent.
Chugai Pharmaceutical, a drug manufacturer operating in Japan, applied late June for the approval to combine these two virus-neutralizing antibodies, on which Japan’s health ministry will deliver the verdict on Monday.
